Text size
Francois Lo Presti / AFP via Getty Images
Pfizer and Moderna first came out of the gate with vaccines approved for Covid-19, but three other drug manufacturers are following them closely and could help the US and other countries get their immunity faster.
Novavax is launching a study of 30,000 people in the US and Mexico for its vaccine, which could be approved immediately in the spring of 2021.
Novavax
the vaccine uses proteins to trigger an immune response after injection, as well as a substance derived from the evergreen trees of Chile to enhance this response.
Developing vaccines from AstraZeneca and Johnson & Johnson use viral vector technology, in which a modified virus triggers an immune response.
AstraZenecaS
The drug is expected to be approved in the UK this week, and the company said its vaccine “should remain effective” on the version first discovered there.
Up to two million Americans have been vaccinated to date
Pfizer
and Modern drugs, both using synthetic messenger RNA to trigger the body to produce protective antibodies against the virus.
Having more vaccines increases the overall supply and offers options that can be more effective in different sections of the population. President-elect Joe Biden also plans to contribute to the juice supply, citing the Defense Production Act once he takes office in January, according to a member of his Covid-19 advisory committee.
This is an excerpt from The Barron’s Daily newsletter. Subscribe here.
Write to [email protected]